Extracellular Vesicle Therapeutics: Overcoming Characterization, Regulatory, and Manufacturing Challenges for Clinical Success

Extracellular vesicles (EVs) are emerging as one of the most promising new therapeutic modalities, with more than 300 drug candidates currently in development across oncology, neurology, inflammation, and pulmonary diseases. As the field moves closer to its first commercial approvals, developers must address critical challenges in characterization, regulatory alignment, and scalable manufacturing to unlock the full potential of EV-based therapies.

Key Learning Points

1. Discover how EV therapeutics are reshaping the future of biologic drug development.  

2. Understand the characterization challenges that impact product quality, safety, and consistency.

3. Learn how evolving regulatory expectations are influencing EV therapy development and commercialization.

4. Explore the manufacturing strategies needed to achieve scalable and reproducible EV production.